Edward Sitar Insider Trades And CPA Net Worth Details by Dr. Clemen Chiang
Edward Sitar Insider Trades And CPA Net Worth Details 

Edward Sitar Insider Trades And CPA Net Worth Details

Get detailed information on Edward Sitar's Net Worth and Edward Sitar insider trades that make him a successful trader in the market. Check out the article below!

Dr. Clemen Chiang
Dr. Clemen Chiang

Edward J. Sitar holds the position of Chief Financial & Accounting Officer at 9 Meters Biopharma, Inc.

He serves on Timber Pharmaceuticals, Inc.'s board of directors.

He previously served as the CFO of SchoolCare, Inc., Ammon Analytical Laboratories, Inc., Vice President of Finance at Vital Signs, Inc., Chief Financial Officer and Treasurer at MIM Corp., Chief Financial Officer and Executive Vice President at Cadent Holdings, Inc., Chief Financial Officer, Secretary and Treasurer for Cancer Genetics, Inc., Chief Financial Officer for BioScrip, Inc., and Chief Financial Officer for Active Health.

Mr. Sitar also did an undergraduate degree from the Scranton University.

What is Edward J. Sitar's net worth?

The estimated Net Worth of Edward J Sitar is at least $737 Thousand dollars as of 14 September 2021. Mr Sitar owns over 15,000 units of 9 Meters Biopharma stock worth over $334,261 and over the last 9 years he sold NMTR stock worth over $5,199. Also, he earns $397,400 as Chief Financial Officer at 9 Meters Biopharma.

Has Edward J. Sitar been buying or selling shares of Timber Pharmaceuticals?

Edward J. Sitar has not been actively trading shares of Timber Pharmaceuticals during the last quarter. Most recently, on Tuesday, November 23rd, Edward J. Sitar bought 15,000 shares of Timber Pharmaceuticals stock. The stock was acquired at an average cost of $0.46 per share, with a total value of $6,900.00.Learn More on Edward J. Sitar's trading history.

Edward Sitar biography

Edward J. Sitar CPA serves as Director of the Company. Since July 2019, Mr. Sitar has worked as the Chief Financial Officer of Innovate Biopharmaceuticals Inc. (NASDAQ: INNT), a clinical stage biotechnology company. Prior to that, he served as Acting Chief Financial Officer of CareDox, Inc., a technology company, from February 2019 to June 2019 and as the CFO of Ammon Analytical Laboratory, From April 2017 to November 2018, a business that specialises in monitoring for the drug treatment industry.

From March 2014 to February 2017, he was the Chief Financial Officer for Cancer Genetics, Inc. (NASDAQ: CGIX), a business that specialises in precision medicine for oncology. Prior to joining Cancer Genetics, he worked for ActiveHealth Management from August 2010 to December 2012 and served as Chief Financial Officer of Healthagen from January 2013 to December 2013. Healthagen is an Aetna provider that sells health goods and services. He held these positions at Cadent Holdings, Inc., a privately held business that offered three-dimensional digital scanning services to dentists and orthodontists, from April 2001 until May 2010.

Mr. Sitar held these positions at MIM Corporation, now known as BioScrip, Inc., a publicly listed specialized pharmaceutical and pharmacy control management service provider, between August 1998 to April 2001. Mr. Sitar served as Vital Signs, Inc.'s vice president of finance from May 1996 to August 1998. This publicly traded manufacturing company and distributor of single-use pharmaceutical devices. The Controller of Zenith was Mr. Sitar from June 1993 until April 1996. He worked for the public accounting company Coopers & Lybrand from 1982 to July 1993. He graduated from the University of Scranton with a B.S. in accounting, and New Jersey has granted him a certification as a Certified Public Accountant.

Mr CPA NMTR stock SEC Form 4 insiders trading

Based on the Form 4 submitted to the SEC, Mr. has traded the stock of 9 Meters Biopharma more than 8 times since 2014. On September 14, 2021, he most recently acquired 15,000 shares of NMTR stock for $18,300.

His largest transaction was the purchase of 61,538 shares of 9 Meters Biopharma stock on December 15, 2020, for a total cost of more than $40,000. Since 2014, Mr. has traded 8,081 shares every 157 days on average. He continued to hold at least 194,338 shares of 9 Meters Biopharma shares as at September 14, 2021.

Insiders trading at 9 Meters Biopharma

Insiders at 9 Meters Biopharma have purchased 2,247,050 shares worth $1,572,701 and sold approximately $20,923,953 worth of the company's stock over the past three years. Mark A. Sirgo, John Temperato, and Israel Gp Ltd.Orbi Med Isra are among the most active insider traders. Executives and board committees of 9 Meters Biopharma typically trade stock every 26 days for an average price of $1,364,538. John Temperato made the most recent stock transaction on July 6, 2022, exchanging 125,000 shares of NMTR stock, which are currently valued $28,750.

What is the work of 9 Meters Biopharma?

The goal of 9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical business, is to develop medicines for people with severe ailments, rare gastrointestinal diseases, and unmet medical requirements. In addition to Vurolenatide, a long-acting injectable glucagon-like peptide-1 throughout Phase 2 clinical experiment for the diagnosis of short bowel syndrome, the company is also going to develop Larazotide, an 8-amino acid peptide that is currently in Phase 3 clinical experiment for the therapies of celiac disease and then in Phase IIa clinical study for the intervention of multi-system inflammatory disorder. Along with these, it creates NM-102, a small molecule peptide, NM-003, a lengthy glucagon-like peptide-2 nicotinic receptor for the treatment of acute graft versus host illness, NM-136, a humanised monoclonal antibody for specific obesity disorders, and NM-004, a double-cleaved mesalamine with just an immunomodulator for orphan and/or rare indications. In Raleigh, North Carolina, the business is headquartered.

Which insiders are now employed by Timber Pharmaceuticals?

  • Timber Pharmaceuticals' insider roster are: John Koconis (CEO),
  • Alan Mendelsohn (Insider), and
  • Edward Sitar (Director).

Spiking Race to 100

We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors' new trades and trade alongside the shoulders of the giants. Try Race to hundred now at spiking.com/race!

Join the Spiking Wealth Community

Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!

*Disclaimer: The article should not be taken as, and is not intended to provide investment advice. Claims made in this article do not constitute investment advice and should not be taken as such. Spiking strongly recommends that you perform your own independent research before making financial decisions